Meriofert Kit

Follicle-Stimulating Hormone and Luteinising Hormone, the active ingredient in Meriofert Kit, is a gonadotropin presented as an injection kit for subcutaneous use. It treats infertility related to anovulation, supports assisted reproductive technologies and manages hypogonadotropic hypogonadism.

GNH USA supplies Meriofert Kit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert Kit, containing FSH and LH, is used in reproductive hormone therapy to stimulate ovarian function.

- Anovulation: induces follicular development and ovulation. - Assisted reproductive technology (IVF): supports controlled ovarian stimulation for egg retrieval. - Hypogonadotropic hypogonadism: replaces deficient gonadotropins to restore normal menstrual cycles.

Adverse reactions to Meriofert Kit may vary in frequency and severity.

Common Side Effects: - Injection site pain: mild discomfort or erythema at the injection site. - Headache: transient headache reported by some patients. - Nausea: occasional mild nausea. - Ovarian hyperstimulation syndrome (mild): mild abdominal discomfort and bloating.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe): rapid weight gain, ascites, thromboembolism. - Allergic reaction: urticaria, angioedema, anaphylaxis. - Ectopic pregnancy: rare occurrence in assisted reproduction cycles.

When using Meriofert Kit, clinicians should observe several precautions to ensure safety and efficacy.

- Patient assessment: evaluate ovarian reserve and baseline hormone levels before initiating therapy. - Monitoring: perform regular ultrasound and estradiol monitoring to adjust dose. - Thromboembolic risk: assess history of clotting disorders, as OHSS can increase risk. - Pregnancy status: avoid use in confirmed pregnancy; therapy is intended for pre‑conception cycles. - Drug interactions: review concomitant medications that may affect ovarian response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert Kit may interact with other agents that influence ovarian response or hemostasis.

Major Interactions (Avoid): - GnRH agonists/antagonists: concurrent use can markedly alter gonadotropin dynamics; coordinate timing. - Anticoagulants: increased risk of bleeding with severe OHSS; monitor coagulation.

Moderate Interactions (Monitor Closely): - Aromatase inhibitors: may reduce estradiol response; adjust dosing. - Clomiphene citrate: overlapping ovulation induction may increase OHSS risk. - Steroids: can affect hormone metabolism; observe clinical response.